Recombinant Human Erythropoietin/EPO Protein

SDS-Page: Recombinant Human Erythropoietin Protein [NBP2-62577]

Product Discontinued

Recombinant Human Erythropoietin/EPO Protein Summary

• Description: Native biologically active mature human EPO, containing 166 amino acid residues, has a predicted molecular mass of approximately 21 kDa. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 36-40 kDa in SDS-PAGE.

  Source: CHO cell line

  Amino Acid Sequence: (Accession #: P01588) APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNFYA WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR GKLKLYTGEA CRTGDR

• Details of Functionality: Fully biologically active when compared to standard. The Specific Activity was measured by the stimulation of reticulocyte production in normocyth-aemic mice and was found to be no less than 1.5 x 10^5 IU/mg.
• Source: CHO
• Protein/Peptide Type: Biologically Active Protein
• Gene: EPO
• Purity: >98%, by SDS-PAGE and HPLC
• Endotoxin Note: Less than 0.01 EU/ug of rHuEPO-alpha as determined by LAL method.

Applications/Dilutions

• Dilutions:
  • Functional
  • SDS-Page
• Theoretical MW: 38 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Sterile filtered liquid in sodium citrate buffer (1 liter of ddH2O containing 5.9 g of sodium citrate, 5.8 g of sodium chloride and 0.06 g of citric acid).
• Preservative: No Preservative
• Purity: >98%, by SDS-PAGE and HPLC

Alternate Names for Recombinant Human Erythropoietin/EPO Protein

• ECYT5
• EP
• EPO
• epoetin
• Erythropoietin
• MGC138142
• MVCD2

Background

Erythropoietin (Epo) stimulates red blood cell production by docking with its cognate receptor on the erythroid progenitor cell and triggering an array of signaling pathways that inhibit apoptosis and promote cell proliferation and differentiation. In its pharmaceutical forms, epoetin and darbepoetin, Epo is widely used to treat various anemias, including those associated with cancer.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 2 years from date of receipt.

Bioinformatics

• Gene Symbol: EPO